September 21, 2015 - The court approved the settlement, the plan of allocation and the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
September 18, 2015 - The court held a final settlement hearing.

May 27, 2015 - The court preliminarily approved the settlement.

April 13, 2015 - Parties filed a stipulation of settlement.

October 1, 2013 - The court denied in part and granted in part the defendants' motion to dismiss and granted lead plaintiffs leave to file an amended complaint.

March 5, 2013 - The lead plaintiffs filed an amended complaint on behalf of investors who purchased shares of Questcor Pharmaceuticals Inc (NASDAQ: QCOR) between April 4, 2011 and September 21, 2012. The plaintiff alleges that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between April 4, 2011 and September 21, 2012.

January 4, 2013 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.

November 26, 2012 - Lead plaintiff motions were filed.

September 26, 2012 - An investor in shares of Questcor Pharmaceuticals Inc (NASDAQ: QCOR) filed a lawsuit in the U.S. District Court for the Central District of California against Questcor Pharmaceuticals Inc over potential securities laws violations in connection with certain allegedly false and misleading statements regarding its injectable drug H.P. Acthar Gel.

Questcor Pharmaceuticals Inc is a biopharmaceutical company. Its primary product is H.P. Acthar Gel (Repository Corticotropin Injection), an injectable drug that is approved by the U. S. Food and Drug Administration (“FDA”) for the treatment of several conditions, including multiple scelorosis, nephrotic syndrome and infantile spasms.

According to the complaint the plaintiff alleges on behalf of purchasers of Questcor Pharmaceuticals Inc (NASDAQ: QCOR) common stock during the period between April 26, 2011 and September 21, 2012, that Questcor Pharmaceuticals Inc and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing between April 26, 2011 and September 21, 2012 allegedly false and misleading statements about the effectiveness of Acthar as a treatment for multiple scelorosis and nephrotic syndrome, making it allegedly impossible for shareholders to gain a meaningful or realistic understanding of the drug’s prospects and market success.

Shares of Questcor Pharmaceuticals Inc (NASDAQ: QCOR) grew from $3.50 per share in November 2009 to as high as $57.64 per share on July 9, 2012.

Then on September 24, 2012, Questcor Pharmaceuticals Inc disclosed in a filing with the Securities and Exchance Commission that on September 21, 2012, Questcor Pharmaceuticals Inc became aware of a U.S. government investigation involving Questcor Pharmaceuticals’ promotional practices.

Last week Aetna Inc said it would limit coverage of Questcor Pharmaceuticals Inc's top-selling drug, H.P. Acthar, a treatment for multiple sclerosis and infant seizures. Aetna issued a Clinical Policy Bulletin stating that based on review of medical studies Acthar was not medically necessary for certain conditions for which it has been prescribed and as a result Aetna would limit the coverage of H.P. Acthar.

Shares of Questcor Pharmaceuticals Inc (NASDAQ: QCOR) dropped from as high as $32.90 per share on September 21, 2012 to as low as $18.90 per share on Monday, September 24, 2012.

On September 26, 2012, Questcor Pharmaceuticals Inc (NASDAQ: QCOR) shares closed at $18.24 per share.